Fellow Directors, Dr. Cheri Walker, interim CEO and Managing Director, and Non-Executive Director, Anthony May. I would also like to introduce our Company Secretary, Mathew Watkins. Raj Kumar, representing BDO, is also in attendance and will make himself available during the meeting to answer any questions on the accounts at the appropriate time. The notice of meeting has been given in accordance with the company's constitution, and copies are available for you on the company website, the share registry website, or ASX announcement platform. Unless there are any objections, I will take the notice of meeting and explanatory statements as read. The format of today's meeting will be a brief summary of the voting and meeting procedures will be provided. Chair address from myself. Presentation from interim CEO and Managing Director, Dr. Cheri Walker, who will provide a general update on the company. We will then take questions from the shareholders on the operations of the company. We will then formally consider the business on today's agenda. We will then take questions from the shareholders in respect to the items of business. After the formal business is considered, we will conduct a poll on all resolutions. Once the poll is completed, the results will be tallied and released on the ASX platform later today. I will now hand over to our Company Secretary, who will explain the voting and question procedures that we will use today. Thank you, Patrick. All shareholders, proxy holders, and authorized corporate representatives, and attorneys of shareholders who are entitled to vote will be able to do so via the webinar poll. If you have lodged a proxy form and voted prior to the meeting, you do not need to vote again at this meeting unless you wish to change your proxy instruction. For proxy holders, shareholders, and authorized corporate representatives who have not yet voted prior to the meeting, please cast your votes on each of the resolutions when the poll is opened. For proxy holders, you will have a summary of proxy votes which detail voting instructions, if any, for each item of business. By completing and voting via the webinar poll, when instructed to vote in a particular manner, you are deemed to have voted in accordance with those instructions. Where the Chair has been appointed proxy on behalf of a shareholder, the Chair of the meeting will be voting in favor of all resolutions. When the poll is declared open, a poll window will appear. To vote, simply select the direction in which you would like to cast your vote, and the option will then be marked. To submit your vote, simply click the submit button. Voting on all resolutions is allowed up until the time the poll is closed. I will outline the procedure for the Q&A sessions as presented on your screen. Prior to asking your questions, we invite you to introduce yourself, and if you are a proxy or corporate representative, who you are representing. If you wish to ask any written questions, please do so via the Q&A function located at the bottom of your screen. To ask a verbal question, please select the raise hand icon, and you will be placed in a queue, and you will be authorized to speak at the appropriate time. Questions of a similar nature will be amalgamated and answered at the relevant time in the meeting. We may experience some time lag, and this may cause some delay in your written questions or comments coming to our attention, so we encourage you to lodge them as early as you can. Thanks, Patrick. Thanks, Mathew. I will now go into the Chair address. Good morning, everyone, and welcome to Atomo Diagnostics' annual general meeting. On behalf of the board, I thank you for joining us today and your continued support of the company. The past year has been a transitional year for Atomo. Navigating a volatile operating environment across the global diagnostics sector, we have continued to execute our strategy on delivering innovative, user-centered, rapid testing solutions that improve access to accurate and reliable diagnostics worldwide. Atomo is starting to fulfill on the promise of its current proprietary HIV franchise and through OEM partnerships, posting significant year-on-year growth of more than 40%. As the company prepares for future global endeavors, Atomo transitioned its Chief Executive role to Dr. Cheri Walker to focus on commercial sales, partnerships, and new product pipeline. We thank John Kelly, the Founding CEO, for his long-term service that has brought Atomo to this exciting juncture. Our focus remains on the patient, providing blood-based testing products that bring increased usability and performance to the patient setting in both the professional use and self-testing settings. The shift to decentralized at point of care and self-testing solution remains strong and growing trend. Government policy and regulators are continuing to see the benefit of point of care and self-testing. My apologies. As new and better tests remove the need for confirmation testing, treatment decisions can be made more rapidly in locations where there is little access to centralized testing or the time that testing could delay life-saving care. Atomo's core purpose remains clear, to simplify and democratize diagnostic testing through our patented device technology. Our products are designed to make testing easier, safer, and more reliable, whether used by a healthcare professional or a self-test user in the home. Over the past year, we have advanced Atomo's Active Syphilis product and added ALT and a Gen 4 HIV to our proprietary product pipeline. Completed projects with two OEM providers for ferritin and brain disease stroke indications. Continued to grow our HIV franchise by more than 40% through international, public health, and pharmacy sales. Made strategic moves to commission a second blister machine in Sydney and started developing new tools to add more flexibility. Plus, began the development of high-cavity moulding meant to improve gross margins. Streamlined our operational model to enhance efficiency and preserve capital. Atomo franchise continues to grow and perform well, providing solid growth of 21% in FY 2026. Atomo's technology is proven, being the first HIV/AIDS self-test to be approved by the Australian Therapeutic Goods Administration, the TGA. We continue to drive growth in international markets, pharmacies, and public health applications across ANZ. Our OEM franchise is starting to drive accelerated growth for Atomo, posting more than 200% year-on-year growth. Atomo is the exclusive licensor, manufacturer, and supplier of the Pascal cassette to Lumos for its FebriDx product. Using Atomo's Pascal cassette, FebriDx has previously secured 510(k) clearance from the US FDA and received CLIA waiver from the US FDA. I just want to focus on the CLIA waiver trial has showed that our Pascal technology, our Pascal cassette, has enabled greater than 99% of concordance between trained and untrained operators using the FebriDx product. That is a key function of our technology. The board remains confident that the company's technology platform, the intellectual property, and strong global relationships position Atomo well to participate in the continuing evolution of decentralized diagnostics. During the year, we undertook a successful capital raising, supporting working capital and enabling us to reshape our organization and position ourselves for the next growth phase. We want to thank existing and new shareholders for their support. In parallel, management have taken decisive steps to reduce cost and strengthen our balance sheet. This financial discipline will support our ability to pursue commercial opportunities in a sustainable manner while continuing to invest selectively in innovation. Looking forward, Atomo's strategy is centered on several priorities, including, one, expanding Atomo's own proprietary test pipeline, such as the Active Syphilis, Liver ALT, and the recently announced HIV Gen 4. Two, leveraging our proven platform and identifying new OEM partnerships in testing applications where usability and accuracy are critical. Our other priority, three, maintaining operational excellence, focused on improving operating scale and gross margins, and prudent capital management as we build towards profitability. I would like to take this opportunity to thank my fellow director, Mr. Anthony May, for his support and guidance. Also, our CEO/MD, Dr. Cheri Walker, and the entire Atomo team for their dedication and professionalism throughout the year. Their efforts have ensured that Atomo continues to be recognized as a leader in user-centric diagnostic design and manufacturing. I would also like to acknowledge the ongoing support of our shareholders. Your confidence in our vision enables us to continue driving innovation in the industry that plays such a vital role in global public health. The board remains committed to delivering long-term value through disciplined execution, strategic partnerships, and continued focus on innovation and quality. Thank you again for your attendance and support. I will now hand over to our CEO, MD, Dr. Cheri Walker, to provide further detail on the company's operational and commercial progress during the year. Thank you, Patrick. I am really excited to be here as the CEO of Atomo Diagnostics, and the reasons haven't changed since I joined the board four years ago. Atomo is a very special company. We have a differentiated platform that provides real value to patients, and who in some cases are self-test consumers, to the clinicians, and to provide a very rapid result. The products provide superior usability and performance, and we will walk you through a lot of that in this presentation. I direct you to our disclaimer, which you can read in the released materials. You can go to the next slide, please. Atomo is all about the patient and the user experience, as Patrick very eloquently spoke about, and it is really the core values of the company that drive the mission. The company has been very focused on having high-impact, innovative products over the last five or six years. When we talk about diving into who Atomo is, we are a commercial. If you go to the next slide, please. We are a commercial-stage company with proven products that are already in the marketplace. We have differentiated technology. Our patented all-in-one blood collection solutions are designed for superior usability, reliability, and performance in these decentralized testing markets. We have proven commercial traction. We have a Gen 3 product franchise that has been generating significant growth over the last several years. In the previous fiscal year, it generated more than 21% growth. When we look at what are the different business lines of the company, we really focus on two areas. Atomo has a growing pipeline of its own proprietary products, and then we also have a point-of-care OEM business. The most famous product currently is the FebriDx product that did receive FDA and CLIA approval in the previous year. You can go to the next slide, please. Atomo has solutions that deliver. When you look at the competing products in the market, they are a collection of many components that require you to basically use an individual lancet, mix those together, collect the blood, and then apply them to the rapid test. This is very difficult in a high-risk setting or, say, an ambulance setting or another medical setting. When you go to what is the solution that Atomo has developed over the years, it is an all-in-one device, and that all-in-one device has a very easy mechanism to lance the finger, to collect the blood, to place that onto the device, and then to hit a button, and that button releases a blister that produces a very specific amount of buffer and provides a very precise assay and assay result. There is also a lot of locking features so that each step has to be done in the right order and in the right way to continue to make progress. It is really these innovations that create a much better user experience, a much easier user experience. You could imagine in an ambulance, for example, it is much easier to basically take the device, prick the finger, collect the blood, do it, hit the button, and look at the results than having to mix and do what you would have to do with the competing technologies. This is really what led to the fact that Lumos Diagnostics did get a CLIA waiver from the U.S. FDA with 99% concordance between the professional and non-professional users. You can go to the next slide, please. All that results in really what are the advantages of the Atomo Pascal and other platforms. It's easy to use, it provides rapid results, and it can be used in a self-test or other setting, remote setting where you can't get access to decentralized testing, or you need to make a decision very quickly. You can go to the next slide, please. At Atomo, we have three platforms that are focused on blood collection. The first is the most advanced, which is the Pascal device, and it is a true all-in-one test where you can basically do all the steps with the single device. Galileo is the platform that is the driver of our current Gen 3 HIV product, very similar to Pascal. You can do the lancet and blood collection in the same device, but then the user has to push the buffer into the device, but still very easy to use and very tried and true in the marketplace. Our newest product is one that was designed to basically help other rapid tests in the market take advantage of the precision of our blister technology, the ability to release a very specific amount of buffer onto the test strip and to do the blood collection and place that onto the device in a very precise way. You can go to the next slide, please. For a small company, Atomo has a very strong regulatory presence, which is critical if you want to be a major player in diagnostic products. These are regulated products on a global basis, and these products have been successfully navigating the different regulatory environments on a global basis. Our future focus for this year is moving towards MDSAP. As we've discussed, and we'll discuss a little bit more, we have an active program where we're entering clinical trials for our Active Syphilis test. The first registrations are expected to be for TGA and for CE marking under IVDR. Then we announced recently our Gen 4 HIV program as well. Go to the next slide, please. Atomo has two proven engines for commercial growth. The first is our Atomo-branded products. These are our proprietary products within our pipeline. When you look at how those products are performing, our Gen 3 HIV franchise produced more than 20% growth in the last year. We also have a growing pipeline of partner products. These are OEM products where we provide our Pascal device to them. They typically put in their own strip, and we provide a blister with their offer, and then they are the legal manufacturer of those products and take those through their own regulatory paths. The most famous of those, of course, right now is FebriDx, and we had more than 200% growth in that business in the last fiscal year. The next slide, please. When we look at our proprietary pipeline, so these are Atomo-branded products. Everyone is aware of our Gen 3 product, which has been in the market for both self-test and screening for a significant period of time. We're going to talk more about our Active Syphilis today, but that is moving rapidly through our pipeline. We recently announced our HIV Gen 4 product. Also in the last year, we were excited to license the Liver ALT test from Burnet, so that product is also moving forward in our pipeline. We're looking at feasibility of a variety of products, including HCV, hepatitis C, and hepatitis B. Go to the next slide, please. Just to remind you, our Gen 3 test is a very robust test. It has almost 100% sensitivity, 99+% specificity, and we have sold more than 5 million tests into the market. Go to the next slide, please. We are really excited to announce that we finished the tech transfer of our Active Syphilis test. It actually exists now in a box format. These are ready to go to clinical trials. Our plan is to start those in the beginning of the next calendar year. It is a pretty exciting test because it not only shows the presence of syphilis, but it can differentiate between whether there is an active case of syphilis versus a case that happened in a previous time period. At this time, it is showing 100% sensitivity, 99% specificity against never-infected patients, and 93% specificity against previously treated cases with a clinical history of syphilis. So far to- date, we are showing 100% concordance with the gold standard testing, which is the RPR test. Go to the next slide, please. We recently announced our Gen 4 HIV partnership. This is a partnership where we will be licensing the proven Gen 4 HIV strip from Innovation Scientific, and they will work with us to be a contract manufacturer to help us with the final packaging and assembly of the product. Our goal is on a similar timeline as syphilis, and this would be to try to get both products to market in the next 18 to 24 months. Go to the next slide, please. Finally, our last product in our proprietary pipeline is the product that we licensed from Burnet Institute. This is a Liver ALT function test, and we are excited about the early performance data and moving this product through our pipeline as well. Go to the next slide, please. In addition to our proprietary products, which we are advancing rapidly through the pipeline, our partners also are moving their products through. FebriDx has been a really exciting story. This product was approved by the US FDA last year and then received CLIA waiver. I would say that we are more than just the FebriDx product. We also have had a long partnership with NG Biotech around a blood pregnancy test. We have announced our projects with Chromacare around ferritin, and we recently revealed our U.K. partner, Upfront Diagnostics, around brain disease and stroke. Go to the next slide, please. Everyone is aware of the FebriDx product. I am not going to steal their thunder and spend a lot of time on this product, but it is a 10-minute test that can show whether it is a viral or bacterial infection. This allows a quick decision about antibiotic usage or not. Go to the next slide, please. We have been seeing nice growth on the Atomo side in the product, so more than 200% growth year-over-year in the last fiscal year. Lumos Diagnostics has announced more than 215 live U.S. sites with a plan to bring many more online over the coming year and incoming flu season. Can we go to the next slide, please? Additionally, we have the other two blood-based tests in the Pascal platform. The NG Biotech blood pregnancy detects pregnancy earlier than some urine tests. Can we go to the next one, please? Next slide, please. We were very excited to announce our partnership with Upfront Diagnostics. Their LVTwo test for brain injury and stroke is a very exciting application. There's a short amount of time where triaging the patients and getting information from them, either in an ambulance or emergency setting, can really make a difference, and we need to triage their care. We're really excited, if you can imagine trying to take all those bottles and components and try to mix them in that kind of setting versus the all-in-one testing. We think that it's really going to be a really nice marriage between our two platforms going forward. All right, we can go to the next slide. We're going to now move into the financial performance for fiscal year 2026. If you go to the next slide, we really view this as a transition year. We're starting to really see the revenue growth pick up from healthy growth in both of our two businesses. Meaning healthy growth in our HIV franchise of proprietary products, as well as growth through our OEM partners. We posted AUD 5.3 million in revenue, a gross margin of 35%, and the underlying EBITDA improved year-over-year to roughly a -AUD 2 million. Go to the next slide, please. We finished the year with a strong balance sheet with AUD 3.7 million in cash. We continue to be debt-free and with total assets of more than AUD 10 million. Go to the next slide, please. We had strong cash flow in the quarter. We had total cash receipts of over AUD 10 million, and this was a combination of AUD 4.6 million in customer receipts, some grant revenue related to our syphilis test, R&D rebate, and then also a fundraising that we did in the fiscal year as well. We ended the year with AUD 3.7 million in cash. Next slide, please. All in all, we think it was a very strong year as we're starting to see the different parts of our business perform across the board, and I think it portends well for the future of Atomo. Go to the next slide, please. As we look at fiscal year 2026 and we start looking forward in 2027, we're really focused on our three imperatives. How do we scale and build these core businesses? How do we improve our gross margins and other margins in the business? How do we expand our pipeline? Because it's really the pipeline of both our proprietary products and our OEM partnerships that are going to drive the future revenue and the future value creation for shareholders going forward. Our first focus is really around our HIV franchise and their market expansion. Now we're really focused on expanding our growth into markets where we have not penetrated with our current Gen 3 assay. We're bringing on new partners and expanding into new markets as we move into 2027. We are continuing to execute on our portfolio expansion. I think we spent a lot of time talking about that, but we're continuing to bring on and evaluate new products to bring into our pipeline. Our syphilis and Gen 4 HIV development projects are going to be a big focus for the company over the next 18 to 24 months as we complete those clinical programs and prepare for the commercial launch of those products. Then moving into Am I online? Am I still on? Okay. Uh-huh. I think so. Yeah, I can hear you. Okay, great. In terms of operations and margins, Patrick hit on this a little bit, but we have brought on new molds that give us higher cavitation. Those will allow us to have better margins and to drop some of our cost of goods. We also moved one of our blister machines under our control here in Sydney, so we've moved those in-house. We continue to focus on different ways to improve our margins going forward. We are focused on our cash discipline. We run a very lean operation, and we will continue to do that. Finally, we really want to drive continued platform adoption, both in our own products, but we're really looking to expand the number of partners that we have out there and really take our Pascal technology platform to a broader market. If you go to the last slide, please. Here, as we start thinking about 2026 and as we're now moving into 2027, we're really focused on building a stronger base, a stronger company that can experience scalable growth. This is how we're really going to drive more shareholder value in the future, to continue to drive new products and the expansion of our current products to bring in more revenue. Then with a continued discipline in terms of our cost structure, start driving to profitability going forward. Our HIV franchise continues to lead the commercial traction. We had more than 25% year-on-year growth. FebriDx really demonstrates the power of our OEM model, and they're not our only partner. They are an important one, but Atomo has much more behind it than the single product of FebriDx. We are really focused on diversifying our revenue over time, and that will lead to a much smoother business with growth across multiple products going forward. I'm really excited to end the presentation here and pass this back to you, Patrick. Thank you, Cheri. Now, we will go to shareholder questions in respect to the operations of the business. Questions in respect to the items of business today will be addressed in the Q&A after the resolutions are put to the meeting. Does any shareholders wish to raise any questions? I remind shareholders to state their name and who they represent prior to asking the question. Matt, are there any questions? There are a few questions. The first from Alice. "If the emphasis is on developing the company's own test, why Innovation Scientific development partnership, and when will it be advised in relation to the commercial terms? Good. I think I'll hand that to Cheri. Yeah, I'm happy to take that question. The model with Innovation Scientific is exactly the same model that the company has optioned in the past. Atomo has not developed its own strip technology capacity, so we have never developed our own test strips to go in our cassettes. In the case of syphilis, in the case of the Liver ALT product, we licensed those strips from Burnet. In the case of the Gen 3 product, we actually have licensed that from another entity as well. In the case of Gen 4, we're licensing a proven test strip from Innovation Scientific. We've looked around at other options. We knew we wanted to bring in Gen 4, and it's a really strong assay that's already been developed. By doing this, we can actually move that program much more quickly into our development program and to market to start bringing in revenue much faster than if we started from scratch or started trying to develop that ourselves when we don't really have those capabilities. It's very much in line with everything that Atomo has done really well in the past, and we did evaluate other opportunities or options around Gen 4. Thanks, Cheri. Mathew, is there any other questions or any other questions from the floor? Yeah, there's one more at the moment, again from Alice. "There's been a report the Chair and our recent large shareholder purchaser, GZ, and Innovation Scientific have connections. Is the company reviewing its assessment of independence in order to protect the interests of smaller shareholders? Maybe I'll direct that to you, Mathew, to- I am more than happy to take that one. Answer some of that. Short answer is yes, the company is. Like any of these circumstances, disclosure of conflicts of interest are regularly looked at if they are changing from time to time. They are talked about as the first thing on each of the company's board meeting agendas. In relation to the independence, the short answer again is yes, that the Chair is independent. We have assessed the criteria in relation to the ASX Corporate Governance Principles and Recommendations and each one of those criteria, and the resolution around that is essentially that the Chair is deemed independent based on the review of the corporate governance recommendations and principles. Thank you, Mathew. Are there any other questions? There is no other questions at this point. On the operations of the business? None at this point. Okay. I will now move to the formal part of the business meet, today's meeting. Before opening the poll, I wish to inform shareholders that the poll will remain open for an additional 30 seconds after we have considered all resolutions. I now declare the poll open. Oops, sorry. The first item for business is to receive and consider the financial report of the company together with the Director's report and Auditor's report for the financial year ending 30th of June 2026. These items are contained in the annual report, so I will ask that they be taken as read. The annual report is available on the ASX announcement platform or on the company's website. The Corporations Act requires the accounts and the reports to be put before shareholders at the annual general meeting. However, except as are set out in resolution one, to be considered later, there is no requirement for a vote of members to be taken on them. We also note that no written questions to the auditor were received by the cutoff date, being five business days before the meeting. For any questions on the audit, these may be directed through myself to the auditor in relation to conduct of the audit, the audit report itself, the company accounting policies, or the independence of the auditor. As this matter does not require a vote, we will now move to the first resolution. I now refer to resolution one, which is to consider the adoption of the remuneration report forming part of the Director's report for the financial year ended 30th of June 2026. The remuneration report is set out in the Director's report at the company's 2026 annual report. The remuneration report sets out the company's remuneration arrangement for Directors, key management personnel of the company. The vote for this resolution is advisory only and does not bind the Directors of or the company. The full resolution is now displayed on the screen, along with proxies received for this resolution. I move that the shareholders consider, and if thought fit, pass the ordinary resolution. As resolution two relates to me, I will now hand the chair to Cheri. Thank you, Patrick. I now refer to resolution two, which relates to the reelection of Mr. Patrick Cook as a Director of the company. The full resolution is displayed on the screen along with the proxy votes received for this resolution. I move the shareholders consider, and if thought fit, pass the ordinary resolution. I will now hand the chair back to Patrick. Thank you. I now refer to resolution three, which relates to the ratification of prior issue of 90.9 million ordinary shares and 45.4 million options as part of the placement. The full resolution is displayed on the screen along with the proxy votes received for this resolution. I move that the shareholders consider, and if thought fit, pass the ordinary resolution. I now refer to resolution four, which relates to the ratification of prior issue of broker options to joint lead managers as part of the placement. The full resolution is now displayed on the screen with the proxy votes received for this resolution. I move that the shareholders consider, and if thought fit, pass the ordinary resolution. I now refer to resolution five, which relates to the ratification of prior issue of 1.3 million ordinary shares and 674,000 options as part of the share purchase plan. The full resolution is displayed on the screen along with the proxy votes received for this resolution. I move that the shareholders consider, and if thought fit, pass this ordinary resolution. I now refer to resolution six, which relates to the approval of the employee option plan. The full resolution is displayed on the screen along with the proxy votes received for this resolution. I move that the shareholders consider, and if thought fit, pass the ordinary resolution. As resolution relates to me, I will now hand the chair to Cheri. Thank you, Patrick. I now refer to resolution seven, which relates to the approval of grant options to Mr. Patrick Cook and/or his nominees. The full resolution is displayed on the screen along with the proxy votes received for this resolution. I move the shareholders consider, and if thought fit, pass the ordinary resolution. I will now hand the chair back to Patrick Cook. Thank you. I now refer to resolution eight, which relates to the approval of grant options to Mr. Anthony May and/or his nominee. The full resolution is displayed on the screen along with the proxy votes received for this resolution. I move that shareholders consider, and if thought fit, pass the ordinary resolution. I now refer to resolution nine, which relates to the approval to grant options to Dr. Cheri Walker and/or her nominees. The full resolution is displayed on the screen along with proxy votes received for this resolution. I move that the shareholders consider, and if thought fit, pass the ordinary resolution. I now refer to resolution 10, which relates to the approval of 10% placement facility under ASX Listing Rule 7.1A. The full resolution is displayed on the screen, along with the proxy votes received for this resolution. I move that the shareholders consider and, if thought fit, pass the special resolution. We will now go to shareholders' questions in respect to these items of business. Does any shareholders wish to raise questions to any of these resolutions? I remind shareholders to state their name and who they represent prior to asking any questions. Just provide a few seconds, Patrick, just to allow any questions. Sure. There are no questions, Patrick. Well, this now concludes the Q&A session for this meeting. We will now provide shareholders with additional 30 seconds for poll voting to be completed. Just a reminder, if any shareholder requires any additional time, just to lodge that request through the Q&A icon located at the bottom of your screen. There's been no requests for additional time, Patrick. Okay. As Chair, I now declare the poll closed. Once the results of the poll has been processed, we will announce the results later today on the ASX market announcement platform. This concludes the formal business part of the meeting. Since the company has not received notice of any other business, we thank you for your attendance, and we look forward to your continued support. Thank you. I will now close the webinar.